H eart failure (HF) remains a major cause of mortality worldwide. It is the cause of ≈5% of the acute hospital admissions, accounting for 10% of the patients in hospital beds in Europe. 1 In the United States, over 5 million people have HF, 2, 3 costing the nation an estimated $32 billion every year. 4 Importantly, the number of patients with HF is steadily increasing, partially as a consequence of an aging population and partially because long-term survival has increased with recent advances in medical therapy and revascularization techniques (eg, percutaneous coronary intervention and coronary artery bypass grafting). In ischemic cardiomyopathy (ICM), almost 90% of the patients with occluded coronary arteries achieve patency after revascularization. However, in ≈25% to 30% of the patients, myocardial reperfusion fails facing much higher risk of developing ventricular remodeling, HF, and death. 5 Additionally, even in those achieving successful revascularization by bypass grafting, decreased survival and recurrence of ischemic symptoms can develop after several years because of restenosis of the vein grafts, progressing to HF. The prognosis of symptomatic HF is poor, with >50% of the patients dying in 4 years after diagnosis and ≈40% of the patients being dead or readmitted to hospital with HF within the first year. 2, 3 HF is characterized by a massive loss of cardiomyocytes, followed by replacement with fibrotic tissue which results in ventricular remodeling and subsequently contractile dysfunction and organ failure.
cases of HF. Management and treatment of DCM has improved significantly in the last decades as a result of optimal medical therapies. Artificial pacemakers or implantable cardioverter-defibrillators may be used in some patients to improve symptoms and reduce hospitalization, but heart transplantation is indicated in patients with advanced disease and refractory to medical therapy. Consequently, there is a clinical need for a complementary or alternative strategy to bring further attenuation or halt the progression of HF. There is also a challenge in developing new treatments that may combine the use of cell therapy with end-stage HF therapies to prevent the progression of the disease.
The rationale behind using stem and progenitor cells as treatment for heart disease is based on the notion that the heart has a limited ability to repair itself after a major injury. Recently, preclinical studies and clinical trials have suggested that stem and progenitor cells may have the potential to ameliorate left ventricular dysfunction after acute myocardial infarction, 8 chronic ischemic, 9 and nonischemic 10 cardiomyopathy and HF. 11 As stand-alone treatment for HF, cell therapies may be restricted, but their potential could be harnessed especially in combination with current advanced HF treatments. Taking the available clinical evidence together, we can conclude that cell-based therapy is safe, with little treatment-related adverse events and no increase in major adverse cardiac events compared with placebo. 12, 13 However, there is substantial clinical heterogeneity in the design of the clinical trials and not all of them confirm the beneficial effect of these cells on both left ventricular function and clinically relevant outcomes.
Despite several challenges, cell therapy remains an exciting novel form of treatment for patients with HF. Recent systematic reviews and meta-analyses have reported benefits of cell therapies on left ventricular function, [14] [15] [16] [17] quality of life (QoL), and exercise tolerance 15, 16, 18 and even a promising reduction in the risk of mortality and rehospitalization as a result of worsening HF. 16 Importantly, one of the more robust tools that modern evidence-based medicine possesses is randomized controlled trials (RCTs). It is therefore imperative that new interventions are evaluated through RCTs wherever possible. Additionally, they are the best at evaluating the cost-effectiveness of a new treatment. We have conducted a previous Cochrane review and meta-analysis, including 23 RCTs of stem and progenitor cells, as treatment for ischemic heart disease and HF. 16 A summary of findings assessment from that study suggested that the quality of the evidence for the reduction in mortality and rehospitalization because of HF was relatively low and likely to change with further research. 16 This conclusion was mainly drawn from a combination of low number of events (deaths) from the contributing RCTs and discordant results from one particular study. 19 During the last year, new clinical evidence has become available in the form of new trials of stem cells treatment for HF patients, which have been completed and reported. 9, 20, 21 In addition, previous meta-analyses have not included trials of cell therapy for DCM. Here we present a new systematic review and meta-analyses evaluating clinical evidence from RCTs of autologous stem and progenitor cells in patients with HF secondary to ischemic and nonischemic cardiomyopathy. The present study includes 14 RCTs which were also included in our previous Cochrane review 16 and 17 new RCTs: 9 RCTs administered bone marrow (BM)-derived cells to patients with ICM, 5 RCTs administered cells from tissues other than BM to patients with ICM, and the remaining 3 RCTs administered BM-derived cells to patients with noniICM (Online Figure I ).
Methods Eligibility
Trials were eligible for inclusion in the meta-analysis if they met all of the following inclusion criteria: (1) randomized or quasi-RCTs, (2) participants presented with symptoms of HF according to the New York Heart Association (NYHA) classification (class II-IV) or clear evidence of LV dysfunction, (3) autologous cell therapy by any route of administration was compared with either no intervention or placebo as treatment for HF, (4) any cointerventions were applied equality in all trial arms. Trials published in any language other than English were excluded, as were trials presented as conference proceedings or published abstract alone. IndMed (1985 onwards) , and the Transfusion Evidence Library (1980 onwards). Searches were not limited by publication date. Detailed search strategies are available from the authors on request. Two reviewers (S.A. Fisher, E. Martin-Rendon) independently screened the titles and abstracts of all remaining references against the full eligibility criteria. The full text of articles was retrieved and screened for all those references for which a decision of eligibility could not be made from title and abstract alone. The reference lists of relevant systematic reviews identified through the search were also checked. Differences of opinion were resolved through discussion with a third reviewer (A. Mathur).
Search Strategy and Study Selection

Data Extraction
Data were extracted onto customized data extractions forms by two reviewers (S.A. Fisher and E. Martin-Rendon) independently; disagreements were resolved through discussion. The reviewers were not blinded to authorship, institutions, journals or the outcomes of trials. Trial details, including study design (objectives, setting, methods of treatment allocation, randomization and blinding, statistical analyses, protocol violations, and conflicts of interest), characteristics of participants (age, sex, inclusion and exclusion criteria, sample sizes), interventions (experimental and control interventions, description of intervention/comparator, timing of intervention, dosage/extent of intervention), and outcomes were recorded. The primary outcomes of this Where multiple times of follow-up were reported, data were extracted for the longest possible duration of shortterm and long-term follow-up. The authors of 18 trials were contacted for clarification of data, including apparent discrepancies and insufficient detail in the reporting of methods or results 19, [22] [23] [24] [25] [26] [27] [28] [29] or for mean and standard deviation values of outcomes where not explicitly reported 11, 19, 25, [30] [31] [32] [33] [34] [35] [36] or where reported graphically. 9, 10, [37] [38] [39] Responses were obtained from authors of 7 trials (see Acknowledgments section). Where possible, for results presented graphically and where actual data values were not forthcoming from study authors (4 studies), mean and standard deviation values were estimated independently by 2 reviewers and the average values were used.
Evaluation of Risk of Bias
Two review authors (S.A. Fisher and E. Martin-Rendon) independently assessed all included trials for possible risk of bias and made explicit judgements about whether trials were at risk of bias according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions. 40 We assessed the design, conduct, and analysis of the trial using a 3-point scale: yes (low risk of bias), no (high risk of bias), or unclear. Assessment of risk of bias for each trial included the following questions: (i) Was the allocation sequence adequately generated? (ii) Was allocation adequately concealed? (iii) Was knowledge of the allocated intervention adequately prevented (ie, blinded) throughout the trial? (iv) Were incomplete outcome data adequately addressed for every outcome? (v) Were reports of the trial free of selective outcome reporting? (vi) Was the trial apparently free of other problems that could put it at risk of bias? Publication bias was assessed for the primary outcome of mortality using a funnel plot.
Data Analysis
Meta-analyses were performed using Revman v5.3. 41 Meta-analyses were restricted to outcomes which were reported in at least three trials. Random effect models were used throughout because of the likely heterogeneity arising from the different cell types and clinical diagnoses. Where standard deviations were not explicitly reported, these were estimated where possible from reported P values or confidence intervals (CI). For continuous outcomes, the mean change from baseline over the study follow-up period was the preferred measure of outcome; the mean value at end point was used where insufficient data were available to calculate the mean change from baseline. Dichotomous data are presented as relative risks (RRs) with 95% CI; continuous measures are presented as the mean difference (MD) with 95% CI between groups at follow-up.
For trials with >2 treatment arms and a single control or placebo group, multiple pairwise comparisons of treatment groups were avoided by pooling treatment groups across different cell types 30 or cell doses. [42] [43] [44] For dichotomous variables, count data were summed across groups and for continuous variables, the mean and standard deviation of the combined group was calculated from the mean and standard deviations of each subgroup.
In the analysis of LVEF, several methods of measurement (MRI, echocardiography, single-photon emission computed tomography, left ventricular angiography) were described, with some trials reporting results for several methods. In the analysis of LVEF, to obtain the most reliable and comparable measurements, results were extracted according to the above order of preference, subject to full availability of the required data.
Several trials reported N-terminal prohormone of BNP (NTproBNP) values rather than BNP. However, the diagnostic performance of these measurements is comparable, and there is no meaningful difference between the 2, despite the differences in measurement scales. 45 Therefore, the standardized MD was used to allow analysis of these 2 comparable measurements on different scales. Where values of NT-proBNP were reported as pmol/L, these were converted to pg/mL using the conversion factor 0.118. 45 The 
Results
Search Results
Electronic database searches identified a total of 4265 records which were screened in duplicate, resulting in 129 potential studies for inclusion. Of these, 93 were subsequently excluded as they failed to meet the inclusion criteria, see PRISMA flow diagram for details ( Figure 1 ). 
Characteristics of the Included Trials
The inclusion criteria were met by 36 full text articles, [9] [10] [11] [42] [43] [44] [48] [49] [50] [51] [52] [53] [54] [55] [56] which described 31 independent trials with a total of 1521 randomized participants (cells, 882; no cells, 639). Two studies 9, 29 randomized participants separately to 2 different cell intervention groups, each with a comparative placebo arm; in these studies, the 2 groups were considered as independent trials unless results were reported for a combined control group, in which case the 2 intervention groups were combined for consistency and to avoid double counting of controls. The characteristics of the included trials are summarized in Table. 10, 48, 54 were of nonischemic DCM; the remaining 28 trials were ICM. The number of participants randomized to these trials ranged from 14 53 to 120 42 and the duration of follow-up ranged from 3 months 30 to 60 months or over. 10, 39, 43, 52 All trials administered standard medical therapy to all participants, including aspirin, clopidogrel, heparin, blockers, cells by magnetic cell separation, and 1 trial enriched in alcohol dehydrogenase-positive cells. 33 Two trials treated patients with granulocyte colony stimulating factor before BM aspiration. 29 One trial mobilized the BM cells into circulation using granulocyte colony stimulating factor and subsequently isolated the mononuclear cell fraction by leukopheresis. 48 One trial obtained BM-derived endothelial progenitor cells from BMMNC by culturing the cells under endothelial culture conditions for 3 days. 52 Of the remaining 8 trials, 3 obtained BM-MSC from BMMNC by culturing the cells under MSC conditions for ≥7 days, 9, 20, 50 one of which treated the BM-MSC with a cardiopoietic cocktail of cytokines before administration. 20 One trial administered cardiac stem cells, obtained from a right atrial appendage biopsy followed by magnetic separation and culture of c-kit-positive cells. 49 The remaining 4 trials isolated SM from muscle biopsies followed by culture of the cells ex vivo and identification of a SM population 37, 42, 44, 51 containing ≥50% of CD56-positive cells. 37, 42, 51 Finally, 1 trial administered adipose-derived regenerative cells obtained by liposuction and followed by enzymatic digestion of the adipose tissue, cell separation, and cell elution using commercially available devices. 21 The cell dose ranged from 5×10 Fifteen trials compared cells with a placebo, 9, 11, 21, 22, 28, 29, [31] [32] [33] [34] [35] 42, 44 generally consisting of a cell-free solution, either the participants own serum or a saline solution containing heparin. One trial used a mock injection procedure in the control arm instead of a cell-free solution. 25 The remaining 15 trials compared treatment to no treatment. 10, 19, 20, 23, 24, 26, 30, 37, [48] [49] [50] [51] [52] [53] [54] Twelve trails delivered the cells via the coronary arteries (IC), 10, 22, 26, [28] [29] [30] 35, [48] [49] [50] 52, 54 whereas the remaining 19 trials injected the cells into the heart muscle (IM). 19 and mortality.
34
Evaluation of Risk of Bias
A summary of the risk of bias of included trials is shown in Figure 2 ; an assessment of the risk of bias of individual trials is shown in Online Table I and Online Figure II . One trial 49 used a 2-staged design whereby the first 13 patients were enrolled consecutively (first 9 allocated to stem cell, followed by 4 allocated to placebo) and subsequent patients were randomized electronically; this trial was deemed to have a high risk of selection bias. included a description of the method of randomization and allocation concealment, which included computerized methods, sealed envelopes, a telephone interactive voice-response system, colored ball selection, random number tables, and site-independent randomization, and the risk of selection bias in these trials was low. In 14 trials, 10, 19, 26, [28] [29] [30] 34, 35, 37, 48, 50, 52, 54 no method of allocation concealment was reported, and therefore, these trials were considered to have an unclear risk of selection bias because of poor allocation concealment.
The risk of performance bias was low in 16 trials, 9 failed to report blinding of outcome assessors.
The risk of attrition bias was low in the majority of trials, with any withdrawals balanced between trial arms and reasons for withdrawal reported. Six trials 20, 23, 42, 48, 49, 54 were deemed to have a high risk of attrition bias because of an unbalanced number of withdrawals between trial arms, and in one case, 48 the number of randomized participants in each trial arm was not reported, and therefore, withdrawals could not be evaluated. In 4 trials, 9,37,44 the risk of attrition bias was unclear as withdrawals, although explained, were unbalanced between trial arms.
All outcomes that were detailed in the trial registration or protocol were reported in 9 trials 9, 11, [21] [22] [23] 25, 30, 33 and had a low risk of reporting bias. In a further 14 trials, 19, 24, 26, 28, 31, 32, 37, 42, 44, 48, [50] [51] [52] [53] all outcomes mentioned in the methods were reported in the results, although it would be difficult to rule out selective reporting, and these trials were therefore considered to have an unclear risk of reporting bias. The risk of bias was also unclear in 7 other trials in which either one predefined secondary outcome was not reported, 20, 34 one reported outcome was not included in the trial registration or protocol, 10, 35, 49 or in the case of 2 trials, 29 interim results of secondary outcomes only were presented. In one trial, 54 the list of predefined outcomes differed between 2 published reports, and this trial was therefore considered to have a high risk of reporting bias. Visual assessment of a funnel plot of the primary outcome of mortality (Online Figure III) did not identify any notable asymmetry suggestive of publication bias, although given the relatively small size of the included trials, small study bias would not be detectable from a funnel plot.
Sources of study funding was reported in 23 trials, including 7 20 ,21,23,33,37,42,44 which reported commercial study sponsorship.
Effect of Interventions
Mortality
Mortality was reported in all but one trial. 48 Twenty-six trials, Figure 3A) . The results remained significant when only ischemic HF trials were included (RR 0.42, 95% CI 0.25-0.71, P=0.001).
Subgroup analysis showed no difference in the risk of mortality between trials grouped according to route of stem cell administration or baseline cardiac function at either shortterm or long-term follow-up (P<0.1 for all comparisons). Insufficient trials were available to evaluate differences according to cell type at short-term follow-up. At long-term follow-up, there was no evidence for a difference in the risk of mortality between trials which used BMMNC (8 trials) and those which used MSC (3 trials; P=0.92).
Rehospitalization Caused by Worsening HF Eight trials 11, [28] [29] [30] 37, 44, 52 (340 participants; 225 treated versus 117 controls) reported rehospitalization caused by worsening HF during short-term follow-up. All were ICM patients. Although 2 trials 29, 52 reported no rehospitalization in either group, in the remaining 5 trials, there were 12/191 patients requiring rehospitalization in the treated group compared with 9/99 in the control group, with no significant difference between groups (RR 0.59, 95% CI 0.25-1.41, P=0. 24) .
However, at long-term follow-up, in 7 trials Figure 3B ). reported summary results only, and in 1 trial of intracoronary administration of cells, 29 only 1 control survived at follow-up and therefore no standard deviation could be calculated. Meta-analysis of the remaining 16 trials showed a significantly lower NYHA class at short-term follow-up in patients who received stem cell treatment compared with those who did not (RR −0.47, 95% CI −0.89 to −0.06, P=0.03; Figure 4A ).
Arrhythmias
NYHA functional class after long-term follow-up was reported as an outcome in 13 trials. 9, 19, 21, 26, 32, 39, 43, [49] [50] [51] [52] 55 Four of those trials were excluded from the meta-analysis: 2 trials 9 reported NYHA class as a proportion of patients whose NYHA class changed from baseline value, 1 trial 39 reported control values graphically with no clear detail of measure of variation, and 1 trial 49 did not report data from the control group at long-term follow-up. Meta-analysis of the remaining 9 trials showed a significantly lower NYHA class in patients who Figure 4B ). These results were confirmed when meta-analysis was restricted to ischemic HF trails (RR −0.72; 95% CI −1.17 to −0.26; P=0.002; I 2 =94%). Considerable statistical heterogeneity was observed at both short-term and long-term follow-up (short-term, I 2 =97%; long-term, I 2 =93%). There was no evidence for a difference in NYHA class between trials grouped according to route of cell administration at either short-term or long-term follow-up. In the comparison of cell types, there was no evidence for a difference in NYHA class between BMMNC and hematopoietic progenitor cells at short-term follow-up (P=0.71). Insufficient trials were available to evaluate differences between cell types at long-term follow-up. When trials were grouped according to baseline cardiac function, there was no difference in NYHA class at short-term follow-up. However, at long-term follow-up, there was some evidence of a difference between trials with mean baseline LVEF <30% (4 trials, MD −1.01, 95% CI −1.45 to −0.58, P<0.00001) and those with mean baseline LVEF >35% (3 trials, MD −0.32, 95% CI −0.74 to 0.10, P=0.14; test for subgroup differences, P=0.03). However, residual heterogeneity remained in both groups (I 2 =84% and I 2 =70%, respectively). of the mean change standard deviation. Meta-analysis revealed a significant difference in mean change from baseline values in favor of cell therapy (MD 2.06%, 95% CI 1.10% to 3.01%, P<0.0001; Figure 5A ). This significant improvement was reflected in 20 trials which reported LVEF values at follow-up (MD 4.66%, 95% CI 2.99% to 6.33%, P<0.00001; Figure 5A ). This effect remained when 2 nonischemic HF trials 48 39 only reported control values graphically with no clear detail of measure of variation and was therefore excluded from the analysis. In another study contributing 2 trials 9 in which results were reported for the 2 control groups combined, results for the 2 intervention groups were also combined for meta-analysis. Figure 5B ). These results were also confirmed in ischemic HF trials only (MD 3.57%, 95% CI 0.30% to 6.84%, P=0.03).
Left Ventricular Ejection Fraction
Moderate statistical heterogeneity was observed at shortterm follow-up for end point analysis (I 2 =61%) and at longterm for both mean change from baseline and end point analyses (I 2 =69% for both analyses). There was no evidence for a difference in LVEF measured at follow-up between trials grouped according to route of cell administration or baseline and 5 trials reported BNP. 19, 26, 35, 44, 48 However, in 1 trial of intracoronary administration of cells, 29 only 1 control survived at follow-up and therefore no standard deviation could be calculated; in another trial, 35 median values were reported, and in a third trial, 44 no standard deviations were reported. In a combined analysis of BNP and NT-proBNP, the remaining 6 trials showed a significant difference in measurements taken at follow-up in favor of cell therapy (standardized MD −0.72 pg/mL, 95% CI −1.41 to −0.02, P=0.04; Figure 6A ).
Four trials reported NT-proBNP 39, 52 or BNP, 26,32 although 1 trial 39 only reported control values graphically with no clear detail of measure of variation and was therefore excluded from the analysis. Meta-analysis of the remaining 3 trials showed no significant difference between groups in measurements taken at long-term follow-up (standardized MD −0.01 pg/mL, 95% CI −1.59 to 1.57, P=0.99).
Considerable statistical heterogeneity was observed at both short-term and long-term follow-up (I 2 =84% and I 2 =92%, respectively).
Exercise Capacity
Exercise capacity at short-term follow-up was reported in 10 trials, 8 of which measured exercise using a 6-minute walk distance test. 9, 19, 20, 23, 35, 37, 44 Other methods of measuring exercise capacity were use of a treadmill test 50 and a bicycle ergometer. 52 Meta-analysis of 4 trials 19, 20, 35, 37 which reported values at the time of follow-up showed a significantly better exercise capacity in patients who received cell treatment than those who did not (MD 65.18 m, 95% CI 9.86-120.5, P=0.02) with considerable heterogeneity across trials (I 2 =80%; Figure 6B ). Meta-analysis of mean change from baseline values at short-term follow-up was not possible as 2 trials reported in one study 9 pooled controls from each trial, and in a third trial, 23 it was unclear whether mean or median values were reported. Seven trials 9, 19, 21, 39, 50, 52 reported exercise capacity at long-term follow-up, although differences in the methods of measurement and reporting prohibited meta-analysis of these trials.
Maximum Oxygen Volume
Maximum oxygen volume was reported in 9 trials, 9, 11, 21, 23, 25, 33, 48, 52 although 2 trials reported in one study 9 only reported brief summary results. In meta-analysis of the remaining 7 trials, there was no significant difference in maximum oxygen volume measured at short-term follow-up (MD 0.27 mL/min/kg, 95% CI −0.29 to 0.83, P=0.35; Figure 6C ). Four trials 9,21,52 reported maximum oxygen volume at long-term follow-up with insufficient data to perform meta-analysis.
Quality of Life
Eleven trials 9, 19, 20, 23, 25, 37, 42, 44, 49, 51 reported QoL measures at short-term follow-up, with all but 1 trial 42 reporting MLHFQ values. Two trials reported in one study 9 reported maximum values (as mean change from baseline) during the study follow-up period; these results were excluded to avoid potential bias. Mean change from baseline values were also reported in 2 other trials, 23, 44 although in one trial, 23 it was unclear whether mean or median values were reported. One trial 20 reported the percentage of patients who improved from baseline score. Meta-analysis of the 5 trials which reported MLHFQ at time of short-term follow-up 19, 25, 37, 49, 51 showed a significant difference between treatment and control groups, demonstrating a significantly better QoL at short-term follow-up in patients who received cell therapy than those who did not (MD −19.6, 95% CI −30.3 to −9.0, P=0.0003; Figure 6D ). Moderate heterogeneity was observed across trials (I 2 =61%). Seven trials 9, 19, 48, 49, 51, 55 reported QoL at long-term followup, although meta-analysis was prohibited by differences in measurement and reporting methods between trials.
Myocardial Perfusion
Myocardial perfusion was reported as an outcome at shortterm follow-up in 10 trials. 11, 19, 21, 23, 25, 28, 33, 34, 50, 53 However, different methods were used across trials, including % reversible defects, 11, 50 % perfusion defect, 28 proportion of LV myocardial segments with a perfusion deficit, 23 summed stress, rest, and difference scores, 19, 21, 33 left ventricular/ infarcted area segmental resting scores, 34 and Technetium ( 99m Tc) sestamibi (MIBI) uptake at rest, 53 and therefore, meta-analysis could not be performed. Of the 10 trials, 4 23, 34, 50, 53 found significant differences between treatment groups at short-term follow-up, whereas 3 11, 28, 33 found no significant differences between groups and 3 19, 21, 25 only reported changes over time within treatment groups. Only 3 trials 19,21,50 reported myocardial perfusion at long-term follow-up, and the different methods of reporting precluded meta-analysis of these trials.
Adverse Events
Peri-procedural adverse events reported in patients who received cell therapy are summarized in Online Table II . Periprocedural adverse events were infrequent and generally related to the interventional procedure rather than the cells themselves, with the exception of arrhythmias reported in 6 trials, 10, 11, 20, 29, 34, 51 including one patient with severely depressed LV function (LVEF 22%) who experienced refractory ventricular fibrillation followed by death on day 3. 34 In addition, 2 patients experienced peri-procedural myocardial infarction 21, 30 and 1 patient who died on postoperative day 7 because of a cardiac unrelated cause (perforated esophageal ulcer complicated by mediastinitis). 31 Adverse events reported at short-and long-term follow-up in patients who received cell therapy as well as those who received no cells are summarized in Online Table III . With the exception of mortality and rehospitalization caused by worsening HF (reported above), meta-analysis of adverse events reported at short-and long-term follow-up was not possible because of disparities in the types of adverse events reported and whether reported episodically or by the number of patients affected.
Sensitivity Analysis
An evaluation of the effect of risk of bias on the significant outcomes of long-term mortality and NYHA functional class and LVEF at short-and long-term follow-up (measured at time of follow-up) was undertaken with sensitivity analyses, excluding those trials with a high or unclear risk of bias caused by randomization methods (allocation), withdrawals or exclusions (attrition bias), and lack of blinding of participants and clinicians (performance bias; see Online Table I and Online Figure II) . When meta-analysis was restricted to those trials reporting appropriate randomization methods, the reduction in the risk of mortality associated with stem cell therapy remained significant (7 trials, RR 0.43, 95% CI 0.25-0.74 P=0.002); similar results were found when only trials with a low risk of attrition bias were included (7 trials; RR . NYHA class and LVEF were similarly robust to both selection and attrition bias, with the exception of LVEF at long-term follow-up (data not shown). However, when only those trials where both clinicians and patients were blinded to treatment, that is, trials with a low risk of performance bias, were included, the beneficial effect of stem cell therapy on risk of mortality at longterm follow-up (5 trials 
Discussion
Cell therapies have the potential to be developed as treatment for HF, [16] [17] [18] but safety and clinical efficacy require further evaluation. The present study is the most comprehensive systematic review and meta-analysis to date of stem cell trials for HF, with 31 included RCTs and a total of 1521 participants. The included trials recruited patients who have been diagnosed with HF and compared the active intervention (cells) with placebo or control (no cells). This systematic review and meta-analysis evaluated, for the first time, clinical data on stem cell treatment for nonischemic DCM. However, the contribution of ischemic HF trials to the main results of the meta-analyses is stronger as only 3 RCTs on cell therapy and nonischemic DCM were eligible for inclusion in this study. Overall, autologous cell-based therapies have been shown to be safe as treatment for HF, with minimal major intervention-related adverse effects and no increase in the incidence of arrhythmias.
The main findings of this systematic review and meta-analyses are as follows: (i) cell treatment is associated with a significant reduction of mortality and rehospitalization caused by worsening HF during long-term follow up, (ii) cell treatment significantly, but moderately, improves global LVEF, (iii) HF symptoms, measured by NHYA functional class and BNP/NT-proBNP levels, are significantly improved by cell treatment, and (iv) the treatment improves exercise capacity and QoL.
An assessment of the risk of bias in the included trials revealed that performance bias, selection bias, and reporting bias contributed the highest risk of bias. Performance bias was considerable as only 52% of the included trials reported blinding of participants and clinicians. Selection bias was also considerable as only 45% of the trials reported the methods of allocation concealment. Finally, 29% of the trials detailed all outcomes measured in the trial registration or protocol, whereas in the remaining 71%, selective reporting bias will be difficult to rule out. This systematic review and metaanalysis does not find evidence of publication bias among the included trials; however, because of the relatively small size of the included trials, this cannot be completely ruled out.
The effect of risk of bias on the significant results was assessed through sensitivity analyses, which will be more stringent than the primary analyses. The conclusion that lower mortality, lower NYHA class, and improved LVEF were associated with cell therapy was robust to inadequate or unreported methods of randomization and to possible attrition bias. However, when trials were restricted to those in which both clinicians and participants were blinded, these significant results were no longer apparent. A consequence of such stringent sensitivity analysis is a substantial reduction in the number of trials included in meta-analyses and hence reduced power to detect a significant effect; this issue can only be resolved through future well-powered and appropriately blinded studies.
A recent study identified a high number of reporting discrepancies in trials of heart disease and concluded that such discrepancies in reporting can lead to bias. 57 However, many of the discrepancies reported by Nowbar and colleagues were in fact a direct consequence of a single misreported sample size or other error, many of which we previously resolved through communication with individual trial authors in our previous systematic review. 16 The same protocol has been adhered to in the present study (see the Acknowledgments section). Further, a large number of discrepancies identified by Nowbar and colleagues originated from nonrandomized studies, 58, 59 and these are not included in our systematic review. Clearly, any discrepancies in reporting can be suggestive of reporting bias and will affect the validity of conclusions that can be drawn. Our experience is that innocuous errors do occur and can often be resolved through communication with study authors.
We have identified 11 previous independent systematic reviews and meta-analyses that have evaluated cell therapies for HF. 12, [14] [15] [16] [17] [18] [60] [61] [62] [63] [64] Seven of these included mortality as an outcome, of which 5 showed no increase in the risk of death after cell treatment, whereas 2 12,16 observed a significant reduction in the risk of mortality associated with cell treatment. One notable difference between the latter 2 systematic reviews is that in our own previous study, 16 we included RCTs for chronic ischemic heart disease and HF (including refractory angina), whereas Jeevanantham and colleagues 12 combined both randomized and nonrandomized trials for chronic ischemic heart disease and acute myocardial infarction. In our previous study, 16 the evidence for a beneficial effect of cell therapy on mortality was drawn from few deaths from the contributing RCTs and notably discordant results from one trial of severe HF. 19 Compared with our previous Cochrane review, 16 the quality of evidence has increased. The present study includes 31 RCTs for HF, 14 of which were also included in our previous Cochrane systematic review and meta-analysis. 16 Importantly, there is a substantial number of new trials included here: 9 trials which administered BMNNC, 4 which used SM, 1 trial which administered cardiac stem cells, and 3 trials in which the participants presented HF secondary to nonischemic DCM. Additionally, the 95% confidence intervals of the RR for the major outcomes have been reduced (Online Table  IV) . However, these results should be considered with caution as the clinical settings for which the treatment is evaluated differ between these 2 reviews. None of the included studies is a Phase III trial, and therefore, they were not designed to detect differences in clinical outcomes, such as mortality.
The present study has greater statistical power than previous by guest on July 1, 2017 http://circres.ahajournals.org/ Downloaded from systematic reviews and meta-analyses, improving the robustness of the evidence and confirming previous results. 16 It has also greater statistical power than the included studies.
In agreement with previous studies, 15 ,18 the present study shows that cell treatment improves patients' QoL (measured by MLHFQ) and exercise capacity (measured by 6-minute walk distance). Cheng et al 18 and Kandala et al 15 reported an improvement in NYHA class in favor of cell treatment but no significant differences in rehospitalization as a result of HF. The latter was also observed in a meta-analysis by Jiang et al. 61 By contrast, Fisher et al 16 reported improved NYHA class and significant decrease in rehospitalization caused by HF, and Jeevanantham et al 12 confirmed a significant reduction in the incidence of HF in favor of cell treatment.
Rehospitalization caused by worsening HF, NYHA functional class, and levels of BNP/NT-proBNP are all surrogates for HF. In this study, we found significant effects with all of these measures, indicative of an amelioration of HF symptoms. Here, the relative risk of rehospitalization caused by HF is reduced to ≈0.40. Although promising, the number of RCTs contributing to this data is relatively small (5 RCTs) with a total of 242 participants included in the meta-analysis.
Of 11 previous systematic reviews and meta-analyses, all but 1 18 demonstrated a moderate but significant improvement in LVEF in favor of cell treatment that ranged from 2.8% to 5.4%. The present study is largely in agreement with previous meta-analyses, although improvement in global LVEF has not been consistently shown in cell therapy trials. 65, 66 The significant reduction in the risk of mortality and rehospitalization caused by HF may be difficult to explain alongside the slight improvement in global LVEF: this question remains unresolved.
Alternative surrogate outcomes have been used to evaluate the efficacy of stem cell therapies. 49, 66 Reduction of scar size is highly predictive of mortality, HF, and LV remodeling. 67, 68 Cell therapies have been shown to reduce scar size significantly in a previous systematic review and meta-analysis in patients with acute myocardial infarction. 13 It is therefore tempting to suggest that in trials for HF, scar size could also be measured as a surrogate outcome to predict clinical efficacy.
Trials included in this study have administered a variety of cell types, BMMNC being the most common therapy. However, there is no current evidence to support that other cell types, such as SM, MSC, or MSC-like cells or cardiac stem cells, do not have similar therapeutic potential. There are only 2 studies among the included RCTs that included different types of cells: BMMNC and BM-MSC 9 and BMMNC and CPC. 30 The number of participants randomized to each arm of these trials is small. Interestingly, Heldman et al 9 showed that BM-MSC performed better than BMMNC at improving 6-minute walk distance and reducing scar mass, thus confirming their regenerative and antifibrotic effect. However, a comparison side by side has not been done yet at a large scale.
If we accept the mechanistic shift that is emerging in the field, most cell therapies seem to be exerting their beneficial effect in a paracrine manner and most probably promoting endogenous repair and regeneration. Repair and regeneration seem to involve tissue remodeling and reduction of scar size. This may explain the discrepancy between the relatively low number of cells administered and the sustained efficacy of the treatment. Cells may be acting as factories that produce an array of growth factors, cytokines, and modulators of extracellular matrix deposition that are required only temporarily. Although the limitations of cell delivery and cell engraftment have been recognized before, 69 cells may not be needed to engraft long-term although still exerting their long-lasting therapeutic benefit. 70 In conclusion, we show that cell therapies may have a clinical benefit for patients with HF, as they seem to significantly reduce mortality and rehospitalization in the long-term. Although promising, these results need to be confirmed in larger appropriately randomized clinical trials in which both clinicans and participants are blinded. However, if confirmed, such a reduction in rehospitalization may mean a real longterm cost saving in the management of HF for any healthcare system.
What Is Known?
• Cell-based therapies have emerged as potential and exciting new interventions to treat heart failure (HF).
• Clinical trials and meta-analyses have shown mixed results, which warrants further evaluation of their safety and clinical efficacy.
What New Information Does This Article Contribute?
• This meta-analysis is the most comprehensive to date and includes cell therapy trials to treat HF secondary to ischemic and nonischemic cardiomyopathy.
• In these settings, cell therapies seem to have a long-term clinical benefit significantly reducing the risk of death and rehospitalization caused by worsening HF. 
